Israel - English - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 500 iu/vial; von willebrand factor 1300 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

Israel - English - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - factor ix, human - pdr+solv for soln for inj - 1000 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - human plasma coagulation factor ii, human plasma coagulation factor vii, human plasma coagulation factor ix, human plasma coagulation factor x, protein c, protein s - pdr+solv for soln for inf - 500 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - human coagulation factor ii, human coagulation factor vii, human coagulation factor ix, human coagulation factor x, protein c, protein s - pdr+solv for soln for inf - 1000 international unit - blood coagulation factors

European Union - English - EMA (European Medicines Agency)

csl behring gmbh - human coagulation factor viii, human von willebrand factor - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrand disease (vwd)prophylaxis and treatment of haemorrhage or surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated.haemophilia a (congenital factor-viii deficiency)prophylaxis and treatment of bleeding in patients with haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - factor viii inhibitor bypassing fraction, quantity: 1000 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; sodium chloride - feiba-nf is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia a or b patients with inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - factor viii inhibitor bypassing fraction, quantity: 1000 u - injection, powder for - excipient ingredients: sodium citrate dihydrate; sodium chloride - feiba-nf is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia a or b patients with inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - factor viii inhibitor bypassing fraction, quantity: 500 u - injection, powder for - excipient ingredients: sodium citrate dihydrate; sodium chloride - feiba-nf is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia a or b patients with inhibitors.